By Reuters |
Topics Coronavirus Vaccine | Pfizer
By Manas Mishra and Michael Erman
(Reuters) - Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.
That timeline makes it unlikely, however, that a vaccine will be available before the U.
S. election, as President Donald Trump has promised. Pfizer, which is developing the vaccine with German partner BioNTech <22UAy.F>, said that it may confirm if the vaccine.
This article is no longer available in our repository.
There could be multiple reasons for this.
You could try searching for this headline on the source website (bloomberg.com).